SLC5A2 and heart failure: The major cardiovascular outcome trials regarding SGLT2 inhibitors showed that cardiovascular risk reduction seen in these studies was mostly driven by a substantial reduction in heart failure risk, which was unexpected (Table 1) [10,11,12].